MovDisordV3, PascalFrancis, Corpus, bibRecord, 000827

Typical Cerebral Metabolic Patterns in Neurodegenerative Brain Diseases

Identifieur interne : 000827 ( PascalFrancis/Corpus ); précédent : 000826; suivant : 000828

Typical Cerebral Metabolic Patterns in Neurodegenerative Brain Diseases

Auteurs : Laura K. Teune ; Anna L. Bartels ; Bauke M. De Jong ; Antoon T. M. Willemsen ; Silvia A. Eshuis ; Jeroen J. De Vries ; Joost C. H. Van Oostrom ; Klaus L. Leenders

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0491625

Descripteurs français

Pascal (Inist)
- Pathologie de l'encéphale, Parkinsonisme, Démence, Pathologie du système nerveux, Encéphale, Maladie métabolique, Glucose(2-désoxy-2-fluor), Tomographie par émission de positons, Diagnostic différentiel.

English descriptors

KwdEn :
- 2-deoxy-2-fluoroglucose, Cerebral disorder, Dementia, Differential diagnostic, Encephalon, Metabolic diseases, Nervous system diseases, Parkinsonism, Positron emission tomography.

Abstract

The differential diagnosis of neurodegenerative brain diseases on clinical grounds is difficult, especially at an early disease stage. Several studies have found specific regional differences of brain metabolism applying [¹⁸F]-fluoro-deoxyglucose positron emission tomography (FDG-PET), suggesting that this method can assist in early differential diagnosis of neurodegenerative brain diseases. We have studied patients who had an FDG-PET scan on clinical grounds at an early disease stage and included those with a retrospectively confirmed diagnosis according to strictly defined clinical research criteria. Ninety-six patients could be included of which 20 patients with Parkinson's disease (PD), 21 multiple system atrophy (MSA), 17 progressive supranuclear palsy (PSP), 10 corticobasal degeneration (CBD), 6 dementia with Lewy bodies (DLB), 15 Alzheimer's disease (AD), and 7 frontotemporal dementia (FTD). FDG PET images of each patient group were analyzed and compared to 18 healthy controls using Statistical Parametric Mapping (SPM5). Disease-specific patterns of relatively decreased metabolic activity were found in PD (contralateral parietooccipital and frontal regions), MSA (bilateral putamen and cerebellar hemispheres), PSP (prefrontal cortex and caudate nucleus, thalamus, and mesencephalon), CBD (contralateral cortical regions), DLB (occipital and parietotemporal regions), AD (parietotemporal regions), and FTD (frontotemporal regions). The integrated method addressing a spectrum of various neurodegenerative brain diseases provided means to discriminate patient groups also at early disease stages. Clinical follow-up enabled appropriate patient inclusion. This implies that an early diagnosis in individual patients can be made by comparing each subject's metabolic findings with a complete database of specific disease related patterns.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 14`
A08	`01`	`1`	`ENG`	`@1 Typical Cerebral Metabolic Patterns in Neurodegenerative Brain Diseases`
A11	`01`	`1`		`@1 TEUNE (Laura K.)`
A11	`02`	`1`		`@1 BARTELS (Anna L.)`
A11	`03`	`1`		`@1 DE JONG (Bauke M.)`
A11	`04`	`1`		`@1 WILLEMSEN (Antoon T. M.)`
A11	`05`	`1`		`@1 ESHUIS (Silvia A.)`
A11	`06`	`1`		`@1 DE VRIES (Jeroen J.)`
A11	`07`	`1`		`@1 VAN OOSTROM (Joost C. H.)`
A11	`08`	`1`		`@1 LEENDERS (Klaus L.)`
A14	`01`			`@1 Department of Neurology, University Medical Center Groningen @2 Groningen @3 NLD @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A14	`02`			`@1 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen @2 Groningen @3 NLD @Z 4 aut. @Z 5 aut.`
A20				`@1 2395-2404`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000192780100190`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 36 ref.`
A47	`01`	`1`		`@0 10-0491625`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The differential diagnosis of neurodegenerative brain diseases on clinical grounds is difficult, especially at an early disease stage. Several studies have found specific regional differences of brain metabolism applying [¹⁸F]-fluoro-deoxyglucose positron emission tomography (FDG-PET), suggesting that this method can assist in early differential diagnosis of neurodegenerative brain diseases. We have studied patients who had an FDG-PET scan on clinical grounds at an early disease stage and included those with a retrospectively confirmed diagnosis according to strictly defined clinical research criteria. Ninety-six patients could be included of which 20 patients with Parkinson's disease (PD), 21 multiple system atrophy (MSA), 17 progressive supranuclear palsy (PSP), 10 corticobasal degeneration (CBD), 6 dementia with Lewy bodies (DLB), 15 Alzheimer's disease (AD), and 7 frontotemporal dementia (FTD). FDG PET images of each patient group were analyzed and compared to 18 healthy controls using Statistical Parametric Mapping (SPM5). Disease-specific patterns of relatively decreased metabolic activity were found in PD (contralateral parietooccipital and frontal regions), MSA (bilateral putamen and cerebellar hemispheres), PSP (prefrontal cortex and caudate nucleus, thalamus, and mesencephalon), CBD (contralateral cortical regions), DLB (occipital and parietotemporal regions), AD (parietotemporal regions), and FTD (frontotemporal regions). The integrated method addressing a spectrum of various neurodegenerative brain diseases provided means to discriminate patient groups also at early disease stages. Clinical follow-up enabled appropriate patient inclusion. This implies that an early diagnosis in individual patients can be made by comparing each subject's metabolic findings with a complete database of specific disease related patterns.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 01`
C03	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 01`
C03	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinsonisme @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinsonism @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson síndrome @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Démence @5 03`
C03	`03`	`X`	`ENG`	`@0 Dementia @5 03`
C03	`03`	`X`	`SPA`	`@0 Demencia @5 03`
C03	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 04`
C03	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 04`
C03	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 04`
C03	`05`	`X`	`FRE`	`@0 Encéphale @5 09`
C03	`05`	`X`	`ENG`	`@0 Encephalon @5 09`
C03	`05`	`X`	`SPA`	`@0 Encéfalo @5 09`
C03	`06`	`X`	`FRE`	`@0 Maladie métabolique @5 10`
C03	`06`	`X`	`ENG`	`@0 Metabolic diseases @5 10`
C03	`06`	`X`	`SPA`	`@0 Metabolismo patología @5 10`
C03	`07`	`X`	`FRE`	`@0 Glucose(2-désoxy-2-fluor) @2 NK @5 11`
C03	`07`	`X`	`ENG`	`@0 2-deoxy-2-fluoroglucose @2 NK @5 11`
C03	`07`	`X`	`SPA`	`@0 Glucosa(2-desoxi-2-fluoro) @2 NK @5 11`
C03	`08`	`X`	`FRE`	`@0 Tomographie par émission de positons @5 12`
C03	`08`	`X`	`ENG`	`@0 Positron emission tomography @5 12`
C03	`08`	`X`	`SPA`	`@0 Tomografía emisión positrones @5 12`
C03	`09`	`X`	`FRE`	`@0 Diagnostic différentiel @5 13`
C03	`09`	`X`	`ENG`	`@0 Differential diagnostic @5 13`
C03	`09`	`X`	`SPA`	`@0 Diagnóstico diferencial @5 13`
C07	`01`	`X`	`FRE`	`@0 Système nerveux central @5 37`
C07	`01`	`X`	`ENG`	`@0 Central nervous system @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso central @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
N21				`@1 326`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0491625 INIST
ET :	Typical Cerebral Metabolic Patterns in Neurodegenerative Brain Diseases
AU :	TEUNE (Laura K.); BARTELS (Anna L.); DE JONG (Bauke M.); WILLEMSEN (Antoon T. M.); ESHUIS (Silvia A.); DE VRIES (Jeroen J.); VAN OOSTROM (Joost C. H.); LEENDERS (Klaus L.)
AF :	Department of Neurology, University Medical Center Groningen/Groningen/Pays-Bas (1 aut., 2 aut., 3 aut., 6 aut., 7 aut., 8 aut.); Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen/Groningen/Pays-Bas (4 aut., 5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 14; Pp. 2395-2404; Bibl. 36 ref.
LA :	Anglais
EA :	The differential diagnosis of neurodegenerative brain diseases on clinical grounds is difficult, especially at an early disease stage. Several studies have found specific regional differences of brain metabolism applying [¹⁸F]-fluoro-deoxyglucose positron emission tomography (FDG-PET), suggesting that this method can assist in early differential diagnosis of neurodegenerative brain diseases. We have studied patients who had an FDG-PET scan on clinical grounds at an early disease stage and included those with a retrospectively confirmed diagnosis according to strictly defined clinical research criteria. Ninety-six patients could be included of which 20 patients with Parkinson's disease (PD), 21 multiple system atrophy (MSA), 17 progressive supranuclear palsy (PSP), 10 corticobasal degeneration (CBD), 6 dementia with Lewy bodies (DLB), 15 Alzheimer's disease (AD), and 7 frontotemporal dementia (FTD). FDG PET images of each patient group were analyzed and compared to 18 healthy controls using Statistical Parametric Mapping (SPM5). Disease-specific patterns of relatively decreased metabolic activity were found in PD (contralateral parietooccipital and frontal regions), MSA (bilateral putamen and cerebellar hemispheres), PSP (prefrontal cortex and caudate nucleus, thalamus, and mesencephalon), CBD (contralateral cortical regions), DLB (occipital and parietotemporal regions), AD (parietotemporal regions), and FTD (frontotemporal regions). The integrated method addressing a spectrum of various neurodegenerative brain diseases provided means to discriminate patient groups also at early disease stages. Clinical follow-up enabled appropriate patient inclusion. This implies that an early diagnosis in individual patients can be made by comparing each subject's metabolic findings with a complete database of specific disease related patterns.
CC :	002B17; 002B17G
FD :	Pathologie de l'encéphale; Parkinsonisme; Démence; Pathologie du système nerveux; Encéphale; Maladie métabolique; Glucose(2-désoxy-2-fluor); Tomographie par émission de positons; Diagnostic différentiel
FG :	Système nerveux central; Pathologie du système nerveux central; Maladie dégénérative
ED :	Cerebral disorder; Parkinsonism; Dementia; Nervous system diseases; Encephalon; Metabolic diseases; 2-deoxy-2-fluoroglucose; Positron emission tomography; Differential diagnostic
EG :	Central nervous system; Central nervous system disease; Degenerative disease
SD :	Encéfalo patología; Parkinson síndrome; Demencia; Sistema nervioso patología; Encéfalo; Metabolismo patología; Glucosa(2-desoxi-2-fluoro); Tomografía emisión positrones; Diagnóstico diferencial
LO :	INIST-20953.354000192780100190
ID :	10-0491625

Links to Exploration step

Pascal:10-0491625

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Typical Cerebral Metabolic Patterns in Neurodegenerative Brain Diseases</title>
<author><name sortKey="Teune, Laura K" sort="Teune, Laura K" uniqKey="Teune L" first="Laura K." last="Teune">Laura K. Teune</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bartels, Anna L" sort="Bartels, Anna L" uniqKey="Bartels A" first="Anna L." last="Bartels">Anna L. Bartels</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Jong, Bauke M" sort="De Jong, Bauke M" uniqKey="De Jong B" first="Bauke M." last="De Jong">Bauke M. De Jong</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Willemsen, Antoon T M" sort="Willemsen, Antoon T M" uniqKey="Willemsen A" first="Antoon T. M." last="Willemsen">Antoon T. M. Willemsen</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eshuis, Silvia A" sort="Eshuis, Silvia A" uniqKey="Eshuis S" first="Silvia A." last="Eshuis">Silvia A. Eshuis</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Vries, Jeroen J" sort="De Vries, Jeroen J" uniqKey="De Vries J" first="Jeroen J." last="De Vries">Jeroen J. De Vries</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Oostrom, Joost C H" sort="Van Oostrom, Joost C H" uniqKey="Van Oostrom J" first="Joost C. H." last="Van Oostrom">Joost C. H. Van Oostrom</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leenders, Klaus L" sort="Leenders, Klaus L" uniqKey="Leenders K" first="Klaus L." last="Leenders">Klaus L. Leenders</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0491625</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0491625 INIST</idno>
<idno type="RBID">Pascal:10-0491625</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000827</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Typical Cerebral Metabolic Patterns in Neurodegenerative Brain Diseases</title>
<author><name sortKey="Teune, Laura K" sort="Teune, Laura K" uniqKey="Teune L" first="Laura K." last="Teune">Laura K. Teune</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bartels, Anna L" sort="Bartels, Anna L" uniqKey="Bartels A" first="Anna L." last="Bartels">Anna L. Bartels</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Jong, Bauke M" sort="De Jong, Bauke M" uniqKey="De Jong B" first="Bauke M." last="De Jong">Bauke M. De Jong</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Willemsen, Antoon T M" sort="Willemsen, Antoon T M" uniqKey="Willemsen A" first="Antoon T. M." last="Willemsen">Antoon T. M. Willemsen</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eshuis, Silvia A" sort="Eshuis, Silvia A" uniqKey="Eshuis S" first="Silvia A." last="Eshuis">Silvia A. Eshuis</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Vries, Jeroen J" sort="De Vries, Jeroen J" uniqKey="De Vries J" first="Jeroen J." last="De Vries">Jeroen J. De Vries</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Oostrom, Joost C H" sort="Van Oostrom, Joost C H" uniqKey="Van Oostrom J" first="Joost C. H." last="Van Oostrom">Joost C. H. Van Oostrom</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leenders, Klaus L" sort="Leenders, Klaus L" uniqKey="Leenders K" first="Klaus L." last="Leenders">Klaus L. Leenders</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>2-deoxy-2-fluoroglucose</term>
<term>Cerebral disorder</term>
<term>Dementia</term>
<term>Differential diagnostic</term>
<term>Encephalon</term>
<term>Metabolic diseases</term>
<term>Nervous system diseases</term>
<term>Parkinsonism</term>
<term>Positron emission tomography</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pathologie de l'encéphale</term>
<term>Parkinsonisme</term>
<term>Démence</term>
<term>Pathologie du   système nerveux</term>
<term>Encéphale</term>
<term>Maladie métabolique</term>
<term>Glucose(2-désoxy-2-fluor)</term>
<term>Tomographie par émission de positons</term>
<term>Diagnostic différentiel</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The differential diagnosis of neurodegenerative brain diseases on clinical grounds is difficult, especially at an early disease stage. Several studies have found specific regional differences of brain metabolism applying [<sup>18</sup>
F]-fluoro-deoxyglucose positron emission tomography (FDG-PET), suggesting that this method can assist in early differential diagnosis of neurodegenerative brain diseases. We have studied patients who had an FDG-PET scan on clinical grounds at an early disease stage and included those with a retrospectively confirmed diagnosis according to strictly defined clinical research criteria. Ninety-six patients could be included of which 20 patients with Parkinson's disease (PD), 21 multiple system atrophy (MSA), 17 progressive supranuclear palsy (PSP), 10 corticobasal degeneration (CBD), 6 dementia with Lewy bodies (DLB), 15 Alzheimer's disease (AD), and 7 frontotemporal dementia (FTD). FDG PET images of each patient group were analyzed and compared to 18 healthy controls using Statistical Parametric Mapping (SPM5). Disease-specific patterns of relatively decreased metabolic activity were found in PD (contralateral parietooccipital and frontal regions), MSA (bilateral putamen and cerebellar hemispheres), PSP (prefrontal cortex and caudate nucleus, thalamus, and mesencephalon), CBD (contralateral cortical regions), DLB (occipital and parietotemporal regions), AD (parietotemporal regions), and FTD (frontotemporal regions). The integrated method addressing a spectrum of various neurodegenerative brain diseases provided means to discriminate patient groups also at early disease stages. Clinical follow-up enabled appropriate patient inclusion. This implies that an early diagnosis in individual patients can be made by comparing each subject's metabolic findings with a complete database of specific disease related patterns.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>14</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Typical Cerebral Metabolic Patterns in Neurodegenerative Brain Diseases</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TEUNE (Laura K.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BARTELS (Anna L.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DE JONG (Bauke M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WILLEMSEN (Antoon T. M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ESHUIS (Silvia A.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>DE VRIES (Jeroen J.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>VAN OOSTROM (Joost C. H.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>LEENDERS (Klaus L.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>2395-2404</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000192780100190</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>36 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0491625</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The differential diagnosis of neurodegenerative brain diseases on clinical grounds is difficult, especially at an early disease stage. Several studies have found specific regional differences of brain metabolism applying [<sup>18</sup>
F]-fluoro-deoxyglucose positron emission tomography (FDG-PET), suggesting that this method can assist in early differential diagnosis of neurodegenerative brain diseases. We have studied patients who had an FDG-PET scan on clinical grounds at an early disease stage and included those with a retrospectively confirmed diagnosis according to strictly defined clinical research criteria. Ninety-six patients could be included of which 20 patients with Parkinson's disease (PD), 21 multiple system atrophy (MSA), 17 progressive supranuclear palsy (PSP), 10 corticobasal degeneration (CBD), 6 dementia with Lewy bodies (DLB), 15 Alzheimer's disease (AD), and 7 frontotemporal dementia (FTD). FDG PET images of each patient group were analyzed and compared to 18 healthy controls using Statistical Parametric Mapping (SPM5). Disease-specific patterns of relatively decreased metabolic activity were found in PD (contralateral parietooccipital and frontal regions), MSA (bilateral putamen and cerebellar hemispheres), PSP (prefrontal cortex and caudate nucleus, thalamus, and mesencephalon), CBD (contralateral cortical regions), DLB (occipital and parietotemporal regions), AD (parietotemporal regions), and FTD (frontotemporal regions). The integrated method addressing a spectrum of various neurodegenerative brain diseases provided means to discriminate patient groups also at early disease stages. Clinical follow-up enabled appropriate patient inclusion. This implies that an early diagnosis in individual patients can be made by comparing each subject's metabolic findings with a complete database of specific disease related patterns.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Démence</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dementia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Demencia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Encephalon</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Maladie métabolique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Metabolic diseases</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Metabolismo patología</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Glucose(2-désoxy-2-fluor)</s0>
<s2>NK</s2>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>2-deoxy-2-fluoroglucose</s0>
<s2>NK</s2>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Glucosa(2-desoxi-2-fluoro)</s0>
<s2>NK</s2>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Tomographie par émission de positons</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Positron emission tomography</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tomografía emisión positrones</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Diagnostic différentiel</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Differential diagnostic</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Diagnóstico diferencial</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fN21><s1>326</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0491625 INIST</NO>
<ET>Typical Cerebral Metabolic Patterns in Neurodegenerative Brain Diseases</ET>
<AU>TEUNE (Laura K.); BARTELS (Anna L.); DE JONG (Bauke M.); WILLEMSEN (Antoon T. M.); ESHUIS (Silvia A.); DE VRIES (Jeroen J.); VAN OOSTROM (Joost C. H.); LEENDERS (Klaus L.)</AU>
<AF>Department of Neurology, University Medical Center Groningen/Groningen/Pays-Bas (1 aut., 2 aut., 3 aut., 6 aut., 7 aut., 8 aut.); Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen/Groningen/Pays-Bas (4 aut., 5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 14; Pp. 2395-2404; Bibl. 36 ref.</SO>
<LA>Anglais</LA>
<EA>The differential diagnosis of neurodegenerative brain diseases on clinical grounds is difficult, especially at an early disease stage. Several studies have found specific regional differences of brain metabolism applying [<sup>18</sup>
F]-fluoro-deoxyglucose positron emission tomography (FDG-PET), suggesting that this method can assist in early differential diagnosis of neurodegenerative brain diseases. We have studied patients who had an FDG-PET scan on clinical grounds at an early disease stage and included those with a retrospectively confirmed diagnosis according to strictly defined clinical research criteria. Ninety-six patients could be included of which 20 patients with Parkinson's disease (PD), 21 multiple system atrophy (MSA), 17 progressive supranuclear palsy (PSP), 10 corticobasal degeneration (CBD), 6 dementia with Lewy bodies (DLB), 15 Alzheimer's disease (AD), and 7 frontotemporal dementia (FTD). FDG PET images of each patient group were analyzed and compared to 18 healthy controls using Statistical Parametric Mapping (SPM5). Disease-specific patterns of relatively decreased metabolic activity were found in PD (contralateral parietooccipital and frontal regions), MSA (bilateral putamen and cerebellar hemispheres), PSP (prefrontal cortex and caudate nucleus, thalamus, and mesencephalon), CBD (contralateral cortical regions), DLB (occipital and parietotemporal regions), AD (parietotemporal regions), and FTD (frontotemporal regions). The integrated method addressing a spectrum of various neurodegenerative brain diseases provided means to discriminate patient groups also at early disease stages. Clinical follow-up enabled appropriate patient inclusion. This implies that an early diagnosis in individual patients can be made by comparing each subject's metabolic findings with a complete database of specific disease related patterns.</EA>
<CC>002B17; 002B17G</CC>
<FD>Pathologie de l'encéphale; Parkinsonisme; Démence; Pathologie du   système nerveux; Encéphale; Maladie métabolique; Glucose(2-désoxy-2-fluor); Tomographie par émission de positons; Diagnostic différentiel</FD>
<FG>Système nerveux central; Pathologie du   système nerveux central; Maladie dégénérative</FG>
<ED>Cerebral disorder; Parkinsonism; Dementia; Nervous system diseases; Encephalon; Metabolic diseases; 2-deoxy-2-fluoroglucose; Positron emission tomography; Differential diagnostic</ED>
<EG>Central nervous system; Central nervous system disease; Degenerative disease</EG>
<SD>Encéfalo patología; Parkinson síndrome; Demencia; Sistema nervioso patología; Encéfalo; Metabolismo patología; Glucosa(2-desoxi-2-fluoro); Tomografía emisión positrones; Diagnóstico diferencial</SD>
<LO>INIST-20953.354000192780100190</LO>
<ID>10-0491625</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000827 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000827 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0491625
   |texte=   Typical Cerebral Metabolic Patterns in Neurodegenerative Brain Diseases
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Typical Cerebral Metabolic Patterns in Neurodegenerative Brain Diseases

Typical Cerebral Metabolic Patterns in Neurodegenerative Brain Diseases

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri